Sign In
Buy IBB
$167.50
+3.23 (+1.97%)
At Close: Jun 03, 2026
3 biotech powerhouses poised to thrive amid sector rebound
10:11am, Friday, 08'th Dec 2023
The biotech sector and its popular ETF, the iShares Biotechnology ETF NASDAQ: IBB, has lagged the overall market during the year. However, in recent weeks, the sector has enjoyed a significant rally a
Biotech reversal confirmed: what's ahead for the IBB?
07:00am, Friday, 08'th Dec 2023
The biotech sector, iShares Biotechnology ETF NASDAQ: IBB, has enjoyed steady buying lately, closing in the green for seven consecutive days. The recent rally comes after the sector ETF broke out of a
2024 Gameplan: 5 Rules to Find Success
08:16am, Friday, 01'st Dec 2023
Breaking down markets to their simplest form can help investors by providing clarity, facilitating better understanding, and aiding decision-making. Stock Strategist Andrew Rocco explains.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
07:31am, Friday, 01'st Dec 2023
Designed to provide broad exposure to the Health Care ETFs category of the market, the iShares Biotechnology ETF (IBB) is a smart beta exchange traded fund launched on 02/05/2001.
A Pending BlackRock ETF to Watch
01:14pm, Thursday, 30'th Nov 2023
Even with $2.4 trillion in ETF assets spread across more than 400 ETFs, there's a pending offering from BlackRock that caught my eye. Before I lose you, dear reader, I'm not talking about the hopefull
IBB: Technicals And Risk Metrics Point To Lower Prices (Technical Analysis)
01:39am, Thursday, 23'rd Nov 2023
Shares of iShares Biotechnology ETF have been trading below their 40-month moving average for almost two years, indicating potential downside risk. The bearish divergences in the fund's RSI momentum i
IBB: Targeting A Buy Point Heading Into Year-End
09:11pm, Tuesday, 21'st Nov 2023
Tech-related stocks have performed poorly in 2023, with small-sized funds experiencing even worse losses. The iShares Biotechnology ETF and the SPDR S&P Biotech ETF have performed similarly so far in
Should You Invest in the iShares Biotechnology ETF (IBB)?
07:31am, Monday, 20'th Nov 2023
If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the iShares Biotechnology ETF (IBB), a passively managed exchange traded fund laun
You Don't Have to Pick a Winner in Biotech. Here's Why.
05:00am, Saturday, 18'th Nov 2023
We all dream of picking tomorrow's big success story, but in reality, we're more likely to win by investing in a variety of players. Biotech offers you plenty of opportunities -- whether you're a caut
"Worst of U.S. Inflation Over"? ETF Areas Likely to Gain
12:02pm, Friday, 17'th Nov 2023
Core inflation for the month of October marked its slowest pace in over two years. Several retailers are also of the view that the worst of inflation is over.
Stock Market ETFs to Watch: Semiconductors (SMH), Biotechnology (IBB), Regional Banks (KRE)
01:29pm, Sunday, 22'nd Oct 2023
Most of you know our Big View product, since I often talk about our risk gauges. In fact, I can report to you that our risk gauges show 3 out of the 5 with risk off.
Goldman Sachs' Chris Shibutani talks his top biotech picks including Eli Lilly and Pfizer
05:43pm, Friday, 29'th Sep 2023
Chris Shibutani, Goldman Sachs Senior Analyst, joins 'Closing Bell Overtime' to talk his top picks in the biotech sectors.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
07:31am, Friday, 29'th Sep 2023
The iShares Biotechnology ETF (IBB) was launched on 02/05/2001, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.
Should You Invest in the iShares Biotechnology ETF (IBB)?
07:31am, Wednesday, 20'th Sep 2023
Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the iShares Biotechnology ETF (IBB) is a passively managed exchange traded fund launched on 02/05/2001.
Time for Gilead Sciences-Heavy ETFs?
03:05pm, Tuesday, 12'th Sep 2023
Bank of America expects the Gilead Sciences to jump about 30%, as quoted on CNBC.
